CANCER CLINICAL TRIALS NEWSLETTER
|
|
This is a 2 phase, multi-center, multiple expansion cohort trial evaluating the safety, PK, metabolites, PD and clinical activity/efficacy of MRTX849 in patients with advanced solid tumor malignancies with KRAS G12C mutation. Efficacy will be measured using Overall survival, objective response rate, and progression free survival rates. MRTX849 will be given to patients in capsules and taken orally once daily. In phase 1, patients will take MRTX849 in varying doses.
In phase 2, once dose level has been determined the study will enroll people into different cohorts for NSCLC, Colon, or rectal cancer.
(849-001, IRB 2020-0118)
|
|
|
Questions? Please call us at 513-584-7698, or email us!
|
|
|
Our phone-based research recruitment app has features updates and a new look! It is available to all UC Cancer Center members and outside colleagues to aid in patient recruitment into cancer and other research studies.
Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? The UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all UC and non-UC referring providers. The new app allows for the entire recruiting portfolio of UC Cancer Center studies to always be updated by the research team. For each study, a summary, inclusion and exclusion criteria, other pertinent study information, and a “one-touch” contact button for the primary research coordinator are included
It takes only seconds to get the new app. On your phone, simply go to https://ctra.highenroll.org. Add the app to your home screen for quick and easy use. Please delete all other prior versions of the app.
If you have any questions, please research out to your UC Cancer Center research team or High Enroll members, Dr. Dylan Steen @ 908-208-6927, dlsteen@highenroll.org or Ginger Conway @859-992-5339, gaconway@highenroll.org.
|
Thanks,
Dylan and Ginger
|
|
|
UC research: Immunotherapy safe for patients with COVID-19, cancer
UC Researchers are examining how immune checkpoint inhibitors, drugs that allow immune cells to respond more strongly, in combination with other treatments, like chemotherapy or radiation, affect the immune cells of COVID-19 patients and patients with both COVID-19 and cancer. Initial research findings show that immunotherapy for cancer won’t worsen complications for COVID-19 patients.
|
|
|
State of the Science Summit: Ovarian Cancer
Thursday, Sep. 3, 2020 | 5:00pm–9:00pm
Renaissance Cincinnati Downtown Hotel
36 E. 4th St. Cincinnati, OH 45202
Keynote Speaker:
Thomas Herzog, MD
University of Cincinnati Cancer Center
Ritu Salani, MD
UCLA
For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.
View Flyer as PDF
|
|
CANCER CLINICAL TRIALS NEWSLETTER
|
|
Questions? Please call us at 513-584-7698, or email us!
|
|
|
|
|